Nadolol (SQ-11725): Non-Selective Beta Blocker for Cardiovascular Research

Executive Summary: Nadolol (SQ-11725) is a non-selective beta-adrenergic receptor antagonist with oral bioactivity and a molecular weight of 309.40 g/mol, used extensively in hypertension and angina pectoris research (APExBIO). It acts via beta-adrenergic receptor antagonism, resulting in decreased heart rate and blood pressure, and is a substrate of the OATP1A2 transporter, impacting its pharmacokinetics (Sun et al., 2025). Nadolol is supplied as a solid and must be stored at -20°C to maintain stability; solutions should be used promptly. It is for research use only and not for diagnostic or medical purposes. The APExBIO BA5097 kit is validated for consistent experimental use in cardiovascular disease models.

Biological Rationale

Nadolol (SQ-11725) is a non-selective beta-adrenergic receptor antagonist. It blocks both β1 and β2 adrenergic receptors, leading to reduced sympathetic stimulation of cardiac and vascular tissues (see mechanism summary). This antagonism underlies its capacity to lower heart rate and arterial blood pressure, making it a foundational tool in hypertension, angina pectoris, and vascular headache research. Because beta-adrenergic pathways are central to cardiovascular regulation and disease pathogenesis, Nadolol's predictable blockade enables reproducible modeling of human disease mechanisms (compare with transporter biology perspective). Nadolol is also a substrate for the organic anion transporting polypeptide 1A2 (OATP1A2), which can affect its tissue distribution and systemic exposure. This transporter interaction is relevant for studies investigating drug disposition and transporter-mediated pharmacokinetics (Sun et al., 2025).

Mechanism of Action of Nadolol (SQ-11725)

Nadolol competitively antagonizes beta-adrenergic receptors. By inhibiting both β1 and β2 subtypes, it reduces the effects of endogenous catecholamines (epinephrine, norepinephrine) on the heart and vasculature. This blockade leads to a decrease in heart rate (negative chronotropy), cardiac contractility (negative inotropy), and renin release from the kidney (APExBIO product page). The overall effect is reduced blood pressure and myocardial oxygen demand. Nadolol's oral bioavailability enables straightforward administration in animal models. Its status as an OATP1A2 substrate means transporter expression can modulate absorption, distribution, and clearance, which should be controlled for in experimental designs (Sun et al., 2025).

Evidence & Benchmarks

• Nadolol demonstrates dose-dependent reduction of systolic and diastolic blood pressure in rodent hypertension models (see APExBIO for protocols).
• Competitive beta-adrenergic receptor antagonism by Nadolol is confirmed by receptor binding assays (KD values in the low micromolar range) (summary article).
• OATP1A2 transporter involvement in Nadolol disposition is verified using transfected-HEK293 and Caco-2 cell models, showing altered uptake and intracellular accumulation (DOI:10.1016/j.biopha.2025.118665).
• Pharmacokinetic studies show Nadolol plasma half-life of 20–24 hours in humans, supporting once-daily dosing in translational models (transporters article).
• Cardiovascular disease models using Nadolol support reproducible induction of beta-adrenergic blockade endpoints, as discussed in APExBIO protocols (product page).

Applications, Limits & Misconceptions

Nadolol is routinely used in experimental hypertension, angina pectoris, and vascular headache models. Its non-selectivity allows broad suppression of beta-adrenergic signaling, which is valuable for dissecting sympathetic contributions to disease phenotypes (for scenario-driven troubleshooting, see this guide). Nadolol is not suitable for studies requiring beta-1 selectivity or those targeting central nervous system beta receptors, as it has limited CNS penetration.

Common Pitfalls or Misconceptions

• Nadolol is not beta-1 selective: It blocks both β1 and β2 receptors, so cannot dissect isoform-specific effects (see more).
• Low CNS penetration: Nadolol is highly hydrophilic and does not appreciably cross the blood-brain barrier; not suitable for CNS beta-blockade models.
• Pharmacokinetics affected by OATP1A2 expression: Experimental systems with altered transporter expression may show variable Nadolol distribution and clearance (Sun et al., 2025).
• Not for diagnostic/clinical use: Nadolol (SQ-11725) supplied by APExBIO is for research purposes only.
• Solution stability is limited: Nadolol solutions degrade; prepare fresh and store at recommended conditions (-20°C for solid).

Workflow Integration & Parameters

Integrating Nadolol (SQ-11725) into cardiovascular research workflows involves careful attention to dosing, preparation, and transporter interactions. The compound is supplied as a stable solid (molecular weight 309.40, formula C17H27NO4) and should be stored at -20°C. Solutions are not stable long-term and must be used promptly. Shipping from APExBIO utilizes blue ice for small molecules to preserve product integrity. Experimental readouts should account for OATP1A2-mediated pharmacokinetic variability, especially in models with altered transporter expression (Sun et al., 2025).

For protocols, see the Nadolol (SQ-11725) BA5097 kit at APExBIO. This resource provides detailed guidance on solution prep, dosing regimens, and readout endpoints, ensuring batch-to-batch reproducibility. For advanced systems pharmacology and translational modeling, the article "Nadolol (SQ-11725): Systems Pharmacology for Next-Gen Cardiovascular Models" discusses how to extend basic lab findings into multi-dimensional disease contexts, complementing the current, more protocol-focused overview.

Conclusion & Outlook

Nadolol (SQ-11725) remains a gold standard non-selective beta-adrenergic receptor blocker for cardiovascular research. Its well-characterized mechanism of action, predictable transporter interactions, and validated research supply by APExBIO support reproducible results across hypertension, angina pectoris, and vascular headache models. Ongoing research into transporter-mediated pharmacokinetics, especially OATP1A2, will refine its application in precision medicine approaches. For further details and validated product access, refer to the APExBIO Nadolol (SQ-11725) BA5097 product page.